雷公藤多苷治疗IgA肾病患者的临床研究

发布时间：2018-06-05 14:12

本文选题：雷公藤多苷 + IgA肾病　；参考：《中国临床药理学杂志》2017年19期

【摘要】：目的研究雷公藤多苷治疗IgA肾病患者的临床疗效。方法将40例IgA肾病患者视为试验组,用雷公藤多苷1 mg·kg~(-1)·d~(-1),分3次口服,治疗6个月。另取同期在本院进行健康体检的40例研究对象作为对照组,对照组不做任何处理。用酶联免疫吸附法检测2组患者血清白细胞介素-15(IL-15)、白细胞介素-18(IL-18)水平。分析患者临床疗效,测定2组研究对象血脂及24h尿蛋白沉淀定量指标。结果治疗后,试验组的总有效率达90.00%(36/40例)。治疗前,试验组与对照组的血清IL-15、IL-18水平分别为(79.47±7.46),(344.14±21.49)ng·L~(-1);(61.91±4.88),(95.70±6.78)ng·L~(-1),与对照组比较,差异均有统计学意义(均P0.05)。治疗后,试验组的血清IL-15、IL-18水平分别为(61.76±6.98),(94.49±8.73)ng·L~(-1),与对照组比较,差异均无统计学意义(均P0.05)。治疗前,试验组与对照组的尿红细胞计数、24 h尿蛋白定量分别为(153.00±10.33),(101.30±7.67)per·μL~(-1);(1.99±0.17),(0.48±0.04)g·d~(-1)。对照组比较,差异均有统计学意义(均P0.05)。治疗后,试验组的尿红细胞计数、24 h尿蛋白定量分别为(103.16±7.54)per·μL~(-1),(0.51±0.04)g·d~(-1)。与治疗前相比,差异均有统计学意义(均P0.05);与对照组相比,差异均无统计学意义(均P0.05)。结论雷公藤多苷用于IgA肾病患者中,能有效降低患者血清的IL-15、IL-18水平,改善患者临床症状,且安全性良好。
[Abstract]:Objective to study the clinical effect of tripterygium wilfordii polyglycoside on IgA nephropathy. Methods 40 patients with IgA nephropathy were treated with tripterygium wilfordii (1 mg kg 路kg ~ (-1) by oral administration for 6 months. Another 40 healthy subjects in our hospital were taken as the control group, the control group did not do any treatment. The serum levels of interleukin-15 (IL-15) and interleukin-18 (IL-18) were measured by enzyme-linked immunosorbent assay (Elisa). The clinical efficacy of the patients was analyzed and the quantitative indexes of blood lipid and 24 h urinary protein precipitation were measured. Results after treatment, the total effective rate of the trial group was 90.00R / 36 / 40 cases. Before treatment, the serum IL-15 IL-18 levels in the experimental group and the control group were 79.47 卤7.46 and 344.14 卤21.49)ng respectively. The levels of IL-18 in the experimental group and the control group were 61.91 卤4.88 and 95.70 卤6.78)ng / L, respectively, and there were significant differences between the two groups (all P 0.05). After treatment, the levels of serum IL-15 IL-18 in the experimental group were 61.76 卤6.98 and 94.49 卤8.73)ng / L ~ (-1), respectively, and there was no significant difference between the two groups (all P 0.05). Before treatment, the urine erythrocyte count and 24 h urinary protein in the test group and the control group were 153.00 卤10.33 7.67)per / L, 101.30 卤7.67)per 渭 L ~ (-1) and 1.99 卤0.17 ~ 0.17 ~ 0.48 卤0.04 g / d ~ (-1) of urine protein, respectively. In the control group, the difference was statistically significant (P 0.05). After treatment, the urine erythrocyte count and 24 h urinary protein in the experimental group were 103.16 卤7.54)per 渭 L ~ (-1) and 0.51 卤0.04 g / d ~ (-1), respectively. Compared with before treatment, the difference was statistically significant (all P 0.05), and there was no significant difference compared with control group (all P 0.05). Conclusion Tripterygium wilfordii polyglycosides in IgA nephropathy patients can effectively reduce the serum level of IL-15 IL-18, improve the clinical symptoms of patients, and the safety is good.
【作者单位】：福建医科大学附属泉州第一医院肾内科;
【基金】：泉州市科技计划基金资助项目(2014Z66)
【分类号】：R692.31

【相似文献】